Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections.

Abstract

We examined the clinical efficacy of a combination of arbekacin and fosfomycin in the treatment of various methicillin-resistant Staphylococcus aureus (MRSA) infections. The combination of arbekacin plus fosfomycin displayed 65.4% (17/26) clinical efficacy and 65.4% (17/26) bacteriological efficacy. This combination thus appeared to be an effective regimen… (More)

Topics

  • Presentations referencing similar topics